{
    "clinical_study": {
        "@rank": "43500", 
        "arm_group": [
            {
                "arm_group_label": "SANGUINATE\u2122", 
                "arm_group_type": "Experimental", 
                "description": "PEG-bHb-CO"
            }, 
            {
                "arm_group_label": "Hydroxyurea", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard of care for Sickle Cell treatment, 15 mg/kg."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety of SANGUINATE\u2122 versus Hydroxyurea in\n      patients suffering from Sickle Cell Disease."
        }, 
        "brief_title": "Study of SANGUINATE\u2122 Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Sickle Cell Disease", 
        "condition_browse": {
            "mesh_term": "Anemia, Sickle Cell"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Homozygous (HbSS) Sickle Cell Anemia;\n\n          -  Hb levels: >6g/dL - <10g/dL;\n\n          -  Age : >18 years old;\n\n          -  Frequency of ER hospitalizations < 6x/yr for SCD pain events   documented \"medical\n             history\".\n\n        Exclusion Criteria:\n\n          -  Patients, who are on chronic transfusion program, defined as regular transfusions\n             every 2-8 weeks;\n\n          -  Allergic to Hydroxyurea;\n\n          -  History of clinical significant disease, as determined by the Investigator;\n\n          -  History of allergy or major allergic reaction considered to be clinically significant\n             by the Investigator;\n\n          -  Screening assessments considered to be abnormal by the Investigator;\n\n          -  Patient has sever pulmonary hypertension (index >3 meters per sec);\n\n          -  Donated blood within 60 days of screening or otherwise experienced blood loss of >250\n             mL within the same period;\n\n          -  Intending to begin new concomitant drug therapy or over-the-counter medication\n             anytime from scree4nin to the time of administration of study drug;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848925", 
            "org_study_id": "SGSC-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "SANGUINATE\u2122", 
                "description": "40 mg/mL intravenous infusion.", 
                "intervention_name": "SANGUINATE\u2122", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Hydroxyurea", 
                "description": "Standard of care for Sickle Cell treatment, 15 mg/kg.", 
                "intervention_name": "Hydroxyurea", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Hydroxycarbamide", 
                    "Brand Names includes: Hydria, Droxia."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hydroxyurea"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "SANGUINATE", 
        "lastchanged_date": "August 26, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Angel Hernandez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barranquilla", 
                        "country": "Colombia"
                    }, 
                    "name": "Fundacion BIOS"
                }, 
                "investigator": {
                    "last_name": "Angel Hernandez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Luis F Uribe, MD", 
                    "phone": "57 (2) 680 6407"
                }, 
                "facility": {
                    "address": {
                        "city": "Cali", 
                        "country": "Colombia"
                    }, 
                    "name": "Fundacion Reina Isabel"
                }, 
                "investigator": {
                    "last_name": "Luis F Uribe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kenny M Galvez, MD", 
                    "phone": "57 (4) 4459753"
                }, 
                "facility": {
                    "address": {
                        "city": "Medellin", 
                        "country": "Colombia"
                    }, 
                    "name": "Hospital Pablo TobinUribe"
                }, 
                "investigator": {
                    "last_name": "Kenny M Galvez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nestor Sosa, MD", 
                    "phone": "507 265 5460"
                }, 
                "facility": {
                    "address": {
                        "city": "Panama City", 
                        "country": "Panama"
                    }, 
                    "name": "PAMRI"
                }, 
                "investigator": {
                    "last_name": "Nestor Sosa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Colombia", 
                "Panama"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE\u2122 at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.", 
        "overall_contact": {
            "email": "hmisra@prolongpharma.com", 
            "last_name": "Hemant Misra, PhD"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Pablo Tobin Uribe", 
                "last_name": "Kenny M Galvez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Fundacion Reina Isabel", 
                "last_name": "Luis F Uribe, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Punta Pacifica", 
                "last_name": "Nestor Sosa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Fundacion BIOS", 
                "last_name": "Angel Hernandez, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Panama: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare pain management between SANGUINATE\u2122 and Hydroxyurea using 0-10 Numeric Pain Scale.", 
            "measure": "To Compare SANGUINATE\u2122 and Hydroxyurea in Sickle Cell Disease patients.", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848925"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Prolong Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prolong Pharmaceuticals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}